AstraZeneca plc

09/18/2020 | Press release | Distributed by Public on 09/18/2020 01:06

Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo

Five-year data from the SOLO-1 Phase III trial is the longest follow-up
analysis for any PARP inhibitor in the 1st-line maintenance setting